ASH 2025 | CARDINAL: Phase I study of TERN-701, an allosteric BCR-ABL1 inhibitor, in previously treated CML
Elias Jabbour
• 24 Nov 2025
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the CARDINAL study (NCT06163430), a Phase I trial investigating TERN-701, a novel allosteric BCR-ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML). Dr Jabbour highlights the efficacy of TERN-701, with a high rate of major molecular response (MMR), deepening of response across all subset categories, and a favorable safety profile. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
